Other research analysts have also issued reports about the stock. TheStreet upgraded shares of Gilead Sciences from a c+ rating to a b- rating in a research note on Thursday, September 7th. Deutsche Bank reiterated a buy rating and issued a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Argus upgraded shares of Gilead Sciences from a hold rating to a buy rating and set a $100.00 target price on the stock in a research note on Thursday, August 31st. Berenberg Bank set a $86.00 target price on shares of Gilead Sciences and gave the company a buy rating in a research note on Tuesday, August 29th. Finally, Credit Suisse Group set a $79.00 target price on shares of Gilead Sciences and gave the company a buy rating in a research note on Monday, August 28th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $85.03.
Gilead Sciences (GILD) opened at $79.02 on Thursday. The firm has a market cap of $103,190.00, a price-to-earnings ratio of 8.99, a PEG ratio of -1.68 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period last year, the business posted $2.75 EPS. Gilead Sciences’s revenue was down 13.2% compared to the same quarter last year. sell-side analysts forecast that Gilead Sciences will post 8.53 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a dividend of $0.52 per share. The ex-dividend date was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.66%.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the sale, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 461,666 shares of company stock worth $34,072,567. 1.30% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in GILD. Welch Investments LLC bought a new position in Gilead Sciences during the 3rd quarter valued at about $108,000. Penserra Capital Management LLC lifted its holdings in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the last quarter. Wealthcare Advisory Partners LLC bought a new position in Gilead Sciences during the 3rd quarter valued at about $133,000. Horan Capital Advisors LLC. bought a new position in Gilead Sciences during the 3rd quarter valued at about $144,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences during the 2nd quarter valued at about $147,000. 75.94% of the stock is owned by hedge funds and other institutional investors.
WARNING: This news story was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/14/gilead-sciences-gild-hold-rating-reaffirmed-at-oppenheimer-updated-updated-updated.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.